AbbVie Inc. Stock

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 16:00:13 2024-04-12 EDT 5-day change 1st Jan Change
162.3 USD -2.22% Intraday chart for AbbVie Inc. -4.54% +4.72%
Sales 2024 * 54.6B 75.2B Sales 2025 * 57.8B 79.6B Capitalization 287B 396B
Net income 2024 * 9.71B 13.37B Net income 2025 * 11.38B 15.67B EV / Sales 2024 * 6.24 x
Net Debt 2024 * 53.44B 73.59B Net Debt 2025 * 44.78B 61.67B EV / Sales 2025 * 5.75 x
P/E ratio 2024 *
28.8 x
P/E ratio 2025 *
23.7 x
Employees 50,000
Yield 2024 *
3.85%
Yield 2025 *
4.02%
Free-Float 96.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.22%
1 week-4.54%
Current month-10.88%
1 month-10.30%
3 months-0.07%
6 months+9.43%
Current year+4.72%
More quotes
1 week
160.00
Extreme 160
171.97
1 month
160.00
Extreme 160
182.30
Current year
154.77
Extreme 154.7704
182.89
1 year
130.96
Extreme 130.9601
182.89
3 years
105.56
Extreme 105.56
182.89
5 years
62.55
Extreme 62.55
182.89
10 years
45.45
Extreme 45.45
182.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 12-12-31
Director of Finance/CFO 57 12-12-31
President 53 11-12-31
Members of the board TitleAgeSince
Director/Board Member 63 12-12-31
Director/Board Member 66 12-12-31
Director/Board Member 70 12-12-31
More insiders
Date Price Change Volume
24-04-12 162.3 -3.13% 7,029,475
24-04-11 167.5 -0.89% 3,307,034
24-04-10 169 -0.65% 3,231,664
24-04-09 170.1 +0.20% 5,933,987
24-04-08 169.8 -0.12% 4,744,996

Delayed Quote Nyse, April 12, 2024 at 04:00 pm

More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
162.3 USD
Average target price
184.3 USD
Spread / Average Target
+13.54%
Consensus